SCHEMBL18470199

SCHEMBL18470199

CCN(CC)c1ccc2cc(C(=O)NC(C)C)c(=O)oc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.70
▸ KMT2A Q03164 9/20 0.70
▸ MAPT P10636 8/20 0.70
▸ ALDH1A1 P00352 6/20 0.70
▸ KDM4E B2RXH2 5/20 0.70
▸ MAOB P27338 4/20 0.70
▸ HPGD P15428 4/20 0.70
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ ATM Q13315 3/20 0.70
▸ USP2 O75604 3/20 0.70
▸ HSD17B10 Q99714 3/20 0.70
▸ CYP1A2 P05177 1/20 0.70
▸ CYP2C19 P33261 1/20 0.70
▸ SLC16A3 O15427 1/20 0.70
▸ ALOX15 P16050 1/20 0.70
▸ SLC16A1 P53985 1/20 0.70
▸ NPC1 O15118 1/20 0.62
▸ STAT3 P40763 1/20 0.62
▸ STAT1 P42224 1/20 0.62
▸ RAB9A P51151 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15391030 0.87 MEN1 (0.61) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL29611843 0.86 MEN1 (0.77) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL13524251 0.86 KMT2A (0.74) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL580009 0.86 MEN1 (0.77) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL28709414 0.86 KMT2A (0.60) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL16293207 0.85 KMT2A (0.73) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL13403918 0.84 KMT2A (0.71) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2911015 0.84 MAOB (0.80) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL1105202 0.84 MEN1 (0.74) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL51872 0.83 MEN1 (0.82) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS JMJD7, HM13, APEH MEN1 396/4885KMT2A 2838/4885MAPT 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback